Oncology Peer Review On-The-Go: 1-on-1 with David Johnson: Enveric’s Endocannabinoid Products for Glioblastoma

Podcast

CancerNetwork®’s podcast features an interview with the chairman and CEO of Enveric Biosciences, David Johnson, to discuss the latest in their development of endocannabinoid products.

In this episode, CancerNetwork® sat down for a conversation with David Johnson, chairman and CEO of Enveric Biosciences. Johnson thoroughly discussed the background of the biosciences company and detailed the endocannabinoid products Enveric is developing to positively impact quality of life for patients with glioblastoma and other cancers.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast anywhere podcasts are available.

Recent Videos
Revolutionizing Onco-Dermatology Techniques and Managing Adverse Effects
Revolutionizing Onco-Dermatology Techniques and Managing Adverse Effects
Managing Dermatologic Complications in Oncology
Managing Dermatologic Complications in Oncology
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
2025 ASCO Annual Meeting: The Show and After Show
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Creating an Accommodating Pediatric Cancer Care Experience
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
A Strong Network of Clinicians Makes Cancer Care More Efficient
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Fostering Multidisciplinary Care May Reduce Oncologist Workplace Burnout
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Communication Between Leadership and Clinicians Improves Cancer Care
What Does It Mean to Experience Workplace Burnout as an Oncologist?
What Does It Mean to Experience Workplace Burnout as an Oncologist?
Oncologists Need to Rely Upon NPs, PAs, and NPPs to Overcome Workforce Problems
Oncologists Need to Rely Upon NPs, PAs, and NPPs to Overcome Workforce Problems
Societal Changes, COVID-19 Among Causes of Oncologist Burnout
Societal Changes, COVID-19 Among Causes of Oncologist Burnout
Related Content
Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors

Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors

Chris Ryan
May 31st 2025
Article

T-DXd rechallenge occurred after grade 1 ILD, and was proven safe for patients with breast cancer/solid tumors.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Integrating Oncodermatology Into Multidisciplinary Practice

Integrating Oncodermatology Into Multidisciplinary Practice

Ariana Pelosci
May 26th 2025
Article

Oncodermatology is critical in managing adverse effects from cancer treatments, specifically targeted therapies and immunotherapies.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates

GLP-1 Use Not Linked to Increased Obesity-Related Cancer Rates

Ariana Pelosci
May 22nd 2025
Article

There was a 7% lower incidence of obesity-related cancer with GLP-1 receptor agonist use.

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis

Mary Katherine L. Anderson, MD;James P. Fagerland, MD;Samantha Kohn, MD, MS;Amy C. Cannella, MD;Benjamin A. Teply, MD
May 16th 2025
Article

This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.